CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Kelonia Therapeutics, Inc.
AVM Biotechnology Inc
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Azienda Ospedaliero-Universitaria di Parma
Azienda Ospedaliero-Universitaria di Parma
Baylor College of Medicine
Children's Oncology Group
University Health Network, Toronto
Pierre Fabre Medicament
Pierre Fabre Medicament
Emory University
University of Michigan Rogel Cancer Center
Mayo Clinic
AbbVie
Cancer Research UK
Cancer Research UK
Cancer Research UK
Cancer Research UK
UNC Lineberger Comprehensive Cancer Center
Dana-Farber Cancer Institute
Barbara Ann Karmanos Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Novartis
Columbia University
Shenzhen University General Hospital
University Hospital Muenster
OriCell Therapeutics Co., Ltd.